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Recently (1), we described a new genetic system that is HLA-DQ-related. Two
alleles, 2B3 and TA10, can be recognized serologically. The 2133 specificity
detected with the 11133 mAb was previously described (2) as a DQwl-related
specificity. The TA10 specificity is DQw3-related and was first. described by
Maeda (3) with the TA10 mAb. TA10 can also be detected with alloantisera (4).
Recently, an absolute correlation of the TA10 specificity with a RFLP using a
DQ(O probe has been described (5).
The 2133 and TA10 determinants are in linkage disequilibrium with HLA-DR
specificities. Both specificities are positively associated with DR4 but never occur
together on the same haplotype (1). DR3+, DQw2' haplotypes carry neither 2133
nor TA10.
We wanted to know the molecular localization of these epitopes. Bontrop et
al. (6) saw a polymorphism similar to 2133/TA10 in a study where DQ molecules
isolated from DR4 homozygous typing cells (HTC) focused in different positions.
Furthermore, Tilanus et al. (7) studied RFLP obtained after digestion with
various restriction enzymes and hybridization with a DQO probe. Within a group
of DR4 HTCs, specific fragments were observed, the presence of which closely
associated with both the 2133/TA10 polymorphism as well as the IEF experi-
ments. The pertinent data showing the nearly perfect correlation between the
mAbs, IEF, and RFLP will be summarized in this paper. The 2B3/TA10
polymorphism is apparently independent from HLA-D, at least in DR4 haplo-
types (6, 7). Furthermore, it is genetically determined and linked to HLA, as
shown by family segregation studies (1). The segregation of specific DNA
fragments with 2133 and TA10 was also shown in a family where the mother was
DR3 homozygous, negative for 2133 and TA10, and lacked the specific DNA
fragments in RFLP (7). The father was DR4 homozygous and positive for both
This work was supported in part by the Dutch Foundation for Medical Research (FUNGO), which
is subsidized by the Dutch Organization for the Advancement of Pure Research (ZWO), the J. A.
Cohen Institute for Radiopathology and Radiation Protection (IRS), and the Child Health and
Welfare Fund.
938
￿
J. Exp. MED. © The Rockefeller University Press - 0022-1007/86/09/0938/06 $1 .00
Volume 164 September 1986 938-943SCHREUDER ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
939
2113 and TAIO . Two specific fragments could be shown in his RFLP; one was
inherited by three children that were DR4+, TA 10+, and the other segregated
to the other two children that were DR4+, 2B3+. The latter two children
happened to be diabetic patients.
This observation, together with other reports, suggested that other markers
(i.e., DQ#) in addition to DR4 may influence disease susceptibility, notably to
type I diabetes (5, 8) . Here we present data concerning the DQ-related
TA10/2B3 polymorphism and type I diabetes mellitus, as well as rheumatoid
arthritis.
Materials and Methods
Cells.
￿
14 EBV-transformed cell lines from DR4 homozygous typing cells with HLA-
Dw4, Dw 10, Dw13, Dw 14, and Dw 15 specificities were used as described previously (7).
64 children with type I diabetes mellitus attending the outpatient clinic for diabetes at
the Sophia Children's Hospital in Rotterdam were studied. Blood from 116 patients with
rheumatoid arthritis wasmade availableby Dr. WestedtandDr. Cats from the Department
of Rheumatology of the University Hospital, Leiden.
A group of 297 healthy individuals served as control population for the 2133 and TA10
specificities. In this group, 14 DR3+ DR4+ individuals were observed. In more recently
DR typed controls, another 24 DR3+ DR4+ individuals were also typed for 2113 and
TA 10. All patients and controls were of Dutch caucasoid origin.
Serological Typings.
￿
HLA-DR and DQ typings were performed by two-color fluores-
cence (TCF) (9) or propidium iodide (PI) technique(10) with a set of highly selected class
II antisera. The 2133 and TA10 specificities were determined with the mAbs 11113 and
TA10, respectively (2, 3).
Biochemical Techniques. Southern blot analyses with the DQ# cDNA probe were
performedas describedpreviously (7). Two-dimensional gelelectrophoresiswasconducted
as described by Goyert et al. (11). HLA-DQ molecules were isolated with the DQ-specific
mAb SPV-L3 (12).
Statistical Analysis.
￿
Associations between the TAIO and 2113 specificities and type I
diabetes or rheumatoid arthritis were calculated with the Woolf-Haldane method (13).
Results and Discussion
Serological and Biochemical Studies.
￿
The 2B3/TA10 polymorphism was inves-
tigated in a group of DR4+ HTCs including Dw4, Dw 10, Dw 13, Dw 14, and
Dw 15 specificities. TA 10 was detected on some Dw4 and some Dw 13 HTCs,
which is in agreement with earlier observations (14). 2133 was present on the
majority of HTCs. Two HTCs appeared to carry both the TA 10 and 2133 alleles,
indicating heterozygosity for this DQ-related system .
11 ofthese DR4 HTCs were analyzed at the product level. HLA-DQ molecules
were isolated with a monomorphic anti-DQ mAb SPV-L3 (12). HLA-DQ mole-
cules appeared to focus in three different positions due to S chain pI differences
(6).
The genomic DNAs isolated from the 14 DR4 HTCs were also studied for
RFLP as obtained after digestion with various restriction enzymes and hybridi-
zation with a DW probe (7). When the enzyme Eco RI was used, we saw two
polymorphic fragments of 15 and 20 kb within the RFLP obtained with the DR4
cells.
Table I shows that all 2113+ HTCs contained the DQ02 or DQ03 chain (as
shown by IEF), as well as the 20-kb fragment in RFLP, whereas the presence of940 SCHREUDER ET AL.
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TABLE I
Serologically Defined TA 10 and 2B3 Specificities ofDR4+ HTCs Compared
with Protein Charge Heterogeneity and the TA1012B3 Characteristic DNA
Fragments
NT, Not tested; +, present; -, absent.
TA10 is closely associated with the presence of DQ#I chains and the presence
of a 15-kb fragment . The only exception was an HTC that only had the DQ#2
chain and the 20-kb fragment in RFLP, but was clearly heterozygous for the
serologically defined 2113 and TA10 specificities on four different typing occa-
sions (6, 7).
Both variants of this 2B3/TAIO-related polymorphism were observed within
the groups of Dw4 and Dw13 HTCs. Furthermore, one Dw4 HTC was hetero-
zygous for 2B3/TAI0, as detected by serology, by two-dimensional gel electro-
phoresis, and by Southern blot analyses indicating that this polymorphism is
independent of HLA-D.
2B3/TA10 and Disease Susceptibility.
￿
Previous studies (5, 8), as well as our
observations in a family with two diabetic patients, did suggest that DR4-2B3
and not DR4-TA10 might be associated with susceptibility to type I diabetes.
Therefore, we tested type I diabetes patients and controls for 2113 and TA10 in
addition to HLA-DR, and looked for an association with 2113 and/or TA10. The
data were analyzed taking into account the known DR phenotypes (DR2, 3, and
4) associated with type I diabetes (15). Because only 1 patient out of 65 was
DR2+, we did not include either this patient or DR2+ controls in the analysis. As
shown in Table 11, there was a very significant (relative risk <0.10) negative
association of TA10 with this disease. This was not only the case in DR4+, but
also in DR4- individuals. The only exception was the group of individuals with
the DR4/x phenotype, suggesting that at least in DR4+ individuals, 2113 might
be associated with susceptibility, rather than TA10 with resistance to type I
diabetes. Table III shows that this was not the case. We did not observe a
significant association of 2113 with diabetes in either DR4- or DR4+ individuals,
with the exception of DR3/4 individuals. The latter, however, is also explained
by the negative association with TA10, as shown in Table 11. Therefore, the
simplest interpretation of the data shown in Table II and III is that TA10 is
associated with resistance to type I diabetes, at least in DR2- individuals. The
HTC
mAb
TA10 2113
DQ8
01
chain
02
pl
,03
Eco
15 kb
RI-DW
20 kb
BSM Dw4 - + - + - - +
LRM Dw4 + - + - - + -
MWM Dw4 + - + - - + -
WEN Dw4 + + + + - + +
JSM Dw10 + + - + - - +
2046 Dw10 - + - + - - +
PEA Dw13 + - + - - + -
EDW Dw13 - + NT - +
LS40 Dw14 - + - + - - +
MT Dw14 - + - + - - +
KY Dw14 - + NT - +
Chop Dw14 - + NT - +
YT2 Dw15 - + - - + - +
YOT Dw15 - + - - + - +SCHREUDER ET AL.
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TABLE II
2B3/TA10 and Type I Diabetes: Association ofTA 10 with Resistance
See footnotes for Table II.
* See reference 13.
*The control panel contained 14 DR3/4 individuals, 4 of which were TA10', but it was
extended with 24 DR3/4 individuals.
OIndicates a blank, most probably DR4 homozygotes.
~ x, DR non-2; non-3 ; non-4.
TABLE III
2B3/TA10 and Type 1 Diabetes: No Association of2B3 with Susceptibility
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absence ofa significant association of TA10 in DR4/x individuals suggests that
on certain haplotypes (i.e., DR non-2, non-3, non-4) TA10 may not provide
resistance to type I diabetes in the presence of DR4 on the other haplotype. In
other words, this might indicate a certain interaction between (products of)
haplotypes, such as complementation . This hypothesis may beanswered by family
studies.
That DR4 is indeed also associated with susceptibility in TA10+ individuals
can be seen from the TA10+ rows of Table II; 4 out of 4 TA10+ patients, as
compared with 25 out of 63 (see note) TA10+ controls, were positive for DR4
(relative risk 13.6; p, 0.0025). In conclusion, in addition to the known association
of HLA-DR2 with resistance to type I diabetes (15, 16), theTA10 allele ofHLA-
DQ(3 appears to be a new marker for resistance to this disease. This indicates
that not only HLA-DR but also other genes in the HLA-D region may influence
the development of type I diabetes, as already suggested previously (5, 15-18).
From a previous study (19) we concluded that such genes have to be situated
telomeric from HLA-DP. Therefore, HLA-DQ might not only be a marker for
but rather be the actual resistance gene.
In contrast to these significant effects of the 2B3/TA10 DQ polymorphism on
the development of type I diabetes, no association was observed in a group of
116 rheumatoid arthritis patients (data not shown). This clearly indicates that
different HLA-linked genes confer susceptibility or resistance tothese two HLA-
DR4-associated diseases, confirming previous observations (20).
DR phenotype
2B3 patients 2B3 controls Relative
risk Xs Significance
(Q)
4- 9 12 64 73 0.9 0,10 NS
3/4 23 0 28 10 17.3 6.97 0.005
4/- 8 0 14 2 2.9 0.76 NS
4/x 11 1 33 6 1 .5 0,21 NS
DR pheno-
type
TA 10
patients TA 10 controls Relative
risk* X
s Significance
(p)
4- 0 21 38 100 0.06 7.26 0.005
3/4 0 23 lot 28= 0.06 6.97 0.005
4/-4 0 8 6 10 0.09 4.12 0.05
4/x1 4 8 15 24 0.84 0.08 NS942
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Summary
A new HLA-DQ-related genetic system with two alleles, 2133 and TA10,
defined serologically by mAbs and alloantisera, showed an almost perfect corre-
lation with charge differences on DQ# molecules, as well as with two polymorphic
DNA fragments hybridizing with a DQ# probe and various restriction enzymes
on a panel of 14 DR4+ homozygous typing cells. It was therefore concluded that
the serologically defined alleles 2113 and TA 10 are coded by the DQ# gene and
situated on the HLA-DQ# chain. This 2133/TA10 polymorphism is independent
of HLA-D and segregates with HLA in families . The TA 10 allele appears to be
a new marker for resistance to type I diabetes, which is independent from the
known resistance marker DR2, whereas no association was observed between
this DQ# polymorphism and rheumatoid arthritis.
We thank Drs. F. Koning and H. Maedafor providing us with the 11B3 and TA10 mAbs;
Mrs. J. Parlevliet, E. M . A. Mikulski, and M. C. J. A. van Eggermond for their excellent
technical assistance; and Mrs. Ellen van der Willik-van Harteveld for preparing the
manuscript.
Receivedfor publication 15 April 1986 and in revised form 16 Tune 1986.
References
1 . Schreuder, G. M. Th., H. Maeda, F. Konig, and J. D'Amaro. 1986. TA10 and 2113,
two new alleles in the HLA-DQ region recognized by monoclonal antibodies. Hum.
Immunol. 16:127 .
2 . Koning, F., J. Raghoebar, G. M . Th. Schreuder, R . K. B. Schuurman, and J. W.
Bruning. 1985. A monoclonal antibody detecting an HLA-DQwl related determi-
nant. Tissue Antigens. 26:100.
3 . Maeda, H. 1984. Mouse monoclonal antibody detects a new polymorphic la deter-
minant other than HLA-DR antigen: a possible allele of DC-1 . TissueAntigens. 23 :163 .
4 . Betuel, H ., L. Gebuhrer, G. M. Th. Schreuder, S . F. Goldmann, A. Arnaiz-Villena,
and Z. Layrisse. 1984. Antigen report: HLA-DR5 and its subtypes HLA-DRwl l and
DRw12. In Histocompatibility Testing 1984. E. Albert, M. P. Baur, and W. R. Mayr,
editors. Springer Verlag, Heidelberg, Federal Republic of Germany. 190-192 .
5 . Kim, S. J., S. Holbeck, B. Nisperos, J. A . Hansen, H. Maeda, and G. T. Nepom .
1985. Identification of a polymorphic variant associated with HLA-DQw3 and
characterized by specific restriction sites within the DQ#-chain gene. Proc. Natl. Acad.
Sci. USA. 82:8139.
6 . Bontrop, R. E., G. M. Th. Schreuder, E. M. A. Mikulski, R. T. van Miltenburg, and
M . J. Giphart. 1986 . Polymorphisms within the HLA-DR4 haplotypes. Various DQ
subtypes detected with monoclonal antibodies. Tissue Antigens. 27 :22
7 . Tilanus, M. G. J., B. Morolli, M. C. J. A. van Eggermond, G. M. Th. Schreuder, R .
R. P. de Vries, and M. J . Giphart. 1986. Dissection of HLA class II haplotypes in
HLA-DR4 homozygous individuals. Immunogenetics. 23 :333 .
8 . Owerbach, D., A. Lernmark, P. Platz, L . P. Ryder, L . Rask, P. A. Peterson, and J .
Ludvigsson. 1983 . HLA-D region /3-chain DNA endonuclease fragments differ be-
tween HLA-DR identical healthy and insulin-dependent diabetic individuals. Nature
(Lond. ). 303 :815.
9 . Rood, J. J. van, A. van Leeuwen, and J. S. Ploem. 1976 . Simultaneous detection of
two cell populations by two colour fluorescence and application to the recognition of
B-cell determinants. Nature (Lond.). 262:795 .SCHREUDER ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
94 3
10 . Bruning, J. W., F. H. J. Claas, M. J. Kardol, Q. Lansbergen, A. M. Naipal, and H. J.
Tanke. 1982 . Automated reading of HLA-A, -B, -C typing and screening. The
propidium iodide (PI) method. Hum. Immunol. 5:225 .
11 . Goyert, S. M ., J. E. Shively, and J. Silver. 1982. Biochemical characterization of a
second family of human la molecules, HLA-DS, equivalent to murine I-A subregion
molecules. J. Exp. Med. 156:550.
12. Spits, H., J. Borst, M . J. Giphart, J. Coligan, C. Terhorst, and J. E. de Vries. 1984.
HLA-DC antigens can serve as recognition elements for human cytotoxic T-lympho-
cytes. Eur. J. Immunol.14:299.
13 . Svejgaard, A., C. Jersild, L. Staub Nielsen, and W. F. Bodmer. 1974 . HLA antigens
and disease: statistical and genetical consideration. Tissue Antigens. 4:95.
14 . Schreuder, G. M. Th., 1. Doxiadis, J. Parlevliet, and H. Grosse-Wilde. 1984. HLA-
DR, DQ, LB and TA10 specificities of ninth workshop homozygous typing cells.
Histocompatibility Testing 1984. Albert, E. et al eds. Springer Verlag, Heidelberg,
Federal Republic of Germany. 243-248.
15 . Jongh, B. M. de, G. J. Bruining, G. M. Th. Schreuder, R. K. B. Schuurman, J. K.
Radder, E. van Loghem, P. Meera Khan, G. Hauptmann, and J. J. van Rood. 1984.
HLA and GM in insulin-dependent diabetes in the Netherlands: report on a combined
multiplex family and population study. Hum. Immunol. 10:5 .
16. Contu, L., I. Deschamps, H. Lestradet, J. Hors, M. Schmid, M. Busson, A. Benajam,
A. Marcelli-Barge, and J. Dausset. 1982. HLA haplotype study of 53 juvenile insulin-
dependent diabetic (I.D.D.) families. Tissue Antigens. 20:123 .
17 . Raum, D., Z. Awdeh, E. J. Yunis, C. A. Alper, and K. H. Gubbay. 1984. Extended
major histocompatibility complex haplotypes in type I diabetes mellitus.J. Clin. Invest.
74:449.
18 . Hitman, G. A., J. Sacks, P. Cassell, J. Awad, G. F. Bottazzo, A._C. Tarn, G. Schwartz,
J. P. Monson, and H. Festenstein. 1986 . A DR3-related DX a gene polymorphism
strongly associates with insulin-dependent diabetes mellitus. Immunogenetics. 23 :47 .
19. Jongh, B. M. de, A. Termijtelen, G. J. Bruining, R. R. P. de Vries, and J. J. van
Rood. 1984. Relation of insulin-dependent diabetes mellitus (I.D.D.) and the HLA-
linked SB system. Tissue Antigens. 23 :87.
20. Dawkins, R. L., F. T. Christiansen, P. H. Kay, M. J. Garlepp, J. McCluskey, P. N.
Hollingsworth, and P. J. Zilko. 1983. Disease associations with complotypes, supra-
types and haplotypes. Immunol. Rev. 70:5.